When a toothache becomes a race against a silent killer
It started with a toothache.
A 53-year-old man.
He was healthy, no underlying conditions, living a simple life.
Then He developed PERIODONTAL pain and facial swelling.
Nothing unusual. He went to his local hospital, got antibiotics, and expected to feel better.
But eleven days later, he would be fighting for his life against one of medicine’s deadliest fungal infections — a disease with an ~ 80% mortality rate that was silently eating through his sinuses, invading his brain, and racing toward his brainstem.
And every traditional test said nothing was there.
The antibiotics didn’t work.
Instead of getting better, he got worse. Much worse.
Seven days after that initial toothache, fever arrived with a vengeance.
Then came the headache, not the dull ache of a sinus infection, but the never-ending, pounding pain that signals something catastrophic.
By the time he arrived at the hospital, something indeed terrifying was happening:
His tongue was deviating to the left, his speech was slurred, and neurological signs pointed to brainstem involvement.
This was not just a dental infection anymore. Something WAS INVADING his brain.
The MRI confirmed everyone’s worst fears: a lesion in his brainstem.
The medical team moved fast.
Blood tests showed his white blood cells were SUPER HIGH. His inflammatory markers were through the roof and climbing.
They started aggressive antibiotics: meropenem and linezolid, broad-spectrum weapons against the most dangerous bacteria.
They treated for brainstem encephalitis and purulent gingivitis.
But nothing improved.
They performed a lumbar puncture.
The cerebrospinal fluid showed elevated white cells, a clear evidence of infection in his central nervous system. The intracranial pressure was dangerously high.
Yet when they tested the CSF, everything came back negative.
No fungi. No bacteria. No acid-fast bacilli.
The 1,3-β-D glucan test (G test) and galactomannan antigen test (GM test). The standard fungal screening tests — were both negative.
How do you fight an infection you can’t identify?
They added empiric antifungal therapy with voriconazole, hoping to cover possible fungal infection.
But without knowing what they were treating.
Was it the right antifungal? Was the dose adequate? Were they even fighting the right enemy?
On the fourth day of hospitalization, something horrific appeared.
The patient became unconscious. His fever spiked to 39.6°C. And then the medical team saw something that made their blood run cold:
Black eschar lesions in his outer ear canal, with bloody secretions.
These Black necrotic tissue is a SIGN of TISSUE DEATH from fungal invasion.
Anyone who’s seen mucormycosis knows that black eschar is the harbinger of death. By the time it appears, the fungus has already invaded deep structures, destroying tissue and blood vessels in its path.
New imaging revealed the full horror story:
multiple intracranial soft tissue infections, sinus infections, suppurative otitis media, and gingival infection. The fungus was everywhere, eating through his face and invading his brain.
They cultured everything: external auditory canal secretions, nasal secretions, blood, cerebrospinal fluid.
Every single culture came back negative.
Think about the impossible position this medical team was in.
They had a patient deteriorating before their eyes with obvious invasive infection. Black necrotic lesions. Brainstem involvement. Sky-high inflammatory markers.
But every culture was negative. Every serological test was negative. Every traditional diagnostic method was blind to whatever was killing their patient.
Time was running out, and traditional diagnostics had completely failed.
Did I mention that the team had sent specimen for mNGS?
Within 48 hours of sending the cerebrospinal fluid for metagenomic next-generation sequencing, the answer arrived.
Lichtheimia ramosa!
4 sequence reads detected in the CSF, representing 50% of the bacterial/fungal DNA present.
Lichtheimia ramosa is a species of mucormycetes — the fungi that cause mucormycosis. It’s notoriously difficult to culture, grows slowly in the lab, and often dies during specimen transport.
But mNGS doesn’t need living fungi. It reads the genetic fingerprints left behind.
Here’s what makes mucormycosis so terrifying:
It’s one of the rarest fungal infections. But when it strikes, it kills most of its victims.
Rhino-orbito-cerebral mucormycosis (ROCM)
The type this patient had, is the most common form.
The fungus invades through the nasal passages, then spreads relentlessly into the sinuses, orbits, and brain.
Early symptoms are nonspecific: stuffy nose, headache, facial swelling. Nothing that screams “deadly fungal infection.”
But once it gains a foothold, it moves with devastating speed.
Crossing anatomical barriers that stop most pathogens. And by the time those characteristic black eschars appear, it’s often too late.
Delayed treatment is essentially a death sentence.
Armed with the diagnosis, the treatment plan changed immediately.
The team switched to liposomal amphotericin B, the most effective drug against mucormycosis.
The dead, infected tissue has to be surgically removed by a process called debridement. The otolaryngology team recommended immediate surgery.
The family refused.
They chose conservative treatment. And for four days, it seemed to work. The fever broke. His temperature normalized.
But invasive Rhinocerebral mucormycosis is not cured with drugs alone.
This healthy 53-year-old man, who had walked into a clinic with a toothache less than three weeks earlier, was dying from one of the deadliest fungal infections known to medicine.
What if mNGS had been the first test ?
Could those extra days have made the difference between life and death?
This case proves a fundamental truth in modern medicine: better tools, helps clinicians make better decisions and leads to better outcomes for our patients.
Stay tuned for more Mystery Infection Files — where every case tells a story, and every story carries a lesson.
👋🏿 Hi! I’m Tina Agbaosi, MD -"Better tools lead to better decisions and better outcomes for patients."